{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:27:27Z","timestamp":1765603647295,"version":"3.48.0"},"reference-count":40,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ANR","award":["17-RHUS-0009"],"award-info":[{"award-number":["17-RHUS-0009"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: The current definition of metabolic dysfunction-associated steatotic liver disease (MASLD) relies on a classical assessment of steatosis via liver biopsy, with grades S0\u2013S3 (5\u2013100% fat) potentially underestimating low-grade steatosis. We propose a new, more sensitive classification based on magnetic resonance imaging\u2013proton-density fat fraction (MRI-PDFF), splitting the existing S0 and S1 grades into three classes: new-S0, very early S1 (S1A), and later S1 (S1B). We aimed to determine whether these early S1A\/S1B phenotypes differed clinically or biologically from the new-S0 grade using large population cohorts. Methods: We assessed the prevalence of the new MRI-PDFF\u2014based grades in 29,252 healthy participants from the UK Biobank discovery cohort, 286 outpatients with type 2 diabetes, and in six previously published databases (N = 149,212) using SteatoTest-2 or a proxy. We performed a multimodal assessment of steatosis using longitudinal MRI-PDFF and liver biopsy data (N = 286). Models were used to adjust for phenotypes and overall mortality, controlling for age, sex, and cardiometabolic factors. Results: In the UK Biobank cohort, the prevalences of the new-S0, S1A, and S1B grades were 54%, 26%, and 17%, respectively. Grades S1A and new-S0 were most discriminated by triglycerides (odds ratio [OR]: 2.40, 95% confidence interval [CI]: 2.07\u20132.77, p &lt; 0.00001) and body mass index (BMI; OR: 1.30, 95% CI: 1.27\u20131.33, p &lt; 0.00001), and grades S1A and S1B were most discriminated by triglycerides, BMI, systolic blood pressure (SBP), and glycated hemoglobin (HbA1c). Adjusting for age, sex, SBP, BMI, HbA1c, triglycerides, and high-density lipoprotein\u2013cholesterol) revealed significantly lower 15-year survival in the high-risk group (97.2%, 95% CI: 96.9\u201397.7) versus the low-risk (99.4%, 95% CI: 99.2\u201399.6) group (p &lt; 0.00001). Conclusions: The early trajectory of liver steatosis is undetectable in 26% of middle-aged adults. This early steatosis phenotype differs clinically and biologically from the new-S0 grade in large population cohorts.<\/jats:p>","DOI":"10.3390\/biomedicines13123045","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T11:17:27Z","timestamp":1765451847000},"page":"3045","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3726-7230","authenticated-orcid":false,"given":"Thierry","family":"Poynard","sequence":"first","affiliation":[{"name":"Medical Faculty, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Sorbonne University, 75013 Paris, France"},{"name":"BioPredictive, 75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1589-9368","authenticated-orcid":false,"given":"Olivier","family":"Deckmyn","sequence":"additional","affiliation":[{"name":"BioPredictive, 75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7619-3086","authenticated-orcid":false,"given":"Valentina","family":"Peta","sequence":"additional","affiliation":[{"name":"BioPredictive, 75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raluca","family":"Pais","sequence":"additional","affiliation":[{"name":"Nutrition Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, 75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Van Beers","sequence":"additional","affiliation":[{"name":"Department of Radiology, Beaujon Hospital, 92110 Clichy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Castera","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hospital Beaujon, Assistance Publique-H\u00f4pitaux de Paris, 75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2803-6606","authenticated-orcid":false,"given":"Frederic","family":"Charlotte","sequence":"additional","affiliation":[{"name":"Department of Anatomy Pathology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, 75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Paradis","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beaujon Hospital, 92110 Clichy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Bedossa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beaujon Hospital, 92110 Clichy, France"},{"name":"Liverpat, 75016 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4460-7643","authenticated-orcid":false,"given":"Dominique","family":"Valla","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hospital Beaujon, Assistance Publique-H\u00f4pitaux de Paris, 75013 Paris, France"},{"name":"UMR1149 (CRI), Inserm, Universit\u00e9 Paris Cit\u00e9, 75018 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101271","DOI":"10.1016\/j.jhepr.2024.101271","article-title":"Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021","volume":"7","author":"Feng","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat. Med."},{"key":"ref_3","unstructured":"(2024). European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol., 81, 492\u2013542."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41586-025-09529-3","article-title":"Learning the natural history of human disease with generative transformers","volume":"647","author":"Shmatko","year":"2025","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Karsdal, M., Cox, T.R., Parker, A.L., Willumsen, N., Sand, J.M.B., Jenkins, G., Hansen, H.H., Oldenburger, A., Geillinger-Kaestle, K.E., and Larsen, A.T. (2025). Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics. J. Clin. Med., 14.","DOI":"10.3390\/jcm14061856"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.matbio.2024.06.003","article-title":"The fibroblast hormone Endotrophin is a biomarker of mortality in chronic diseases","volume":"132","author":"Genovese","year":"2024","journal-title":"Matrix Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12933-025-02706-8","article-title":"Interleukin-1\u03b2 in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes","volume":"24","author":"Simeone","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9245699","DOI":"10.1155\/jobe\/9245699","article-title":"Genomic Exploration of Nonalcoholic Fatty Liver Disease: Insights From Gene Expression and Variation in Morbidly Obese Individuals","volume":"2025","author":"Rafaa","year":"2025","journal-title":"J. Obes."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"109037","DOI":"10.1016\/j.jdiacomp.2025.109037","article-title":"Growth differentiation factor-15: A marker for diabetic kidney disease in patients with metabolic-associated fatty liver disease","volume":"39","author":"Shora","year":"2025","journal-title":"J. Diabetes Complicat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1007\/s10620-025-08844-z","article-title":"Clinical Relevancies of Sarcopenic Obesity in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD)","volume":"70","author":"Chien","year":"2025","journal-title":"Dig. Dis. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10652","DOI":"10.1038\/s41598-025-85508-y","article-title":"Non-invasive liver fibrosis markers are increased in obese individuals with non-alcoholic fatty liver disease and the metabolic syndrome","volume":"15","author":"Askeland","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12933-025-02645-4","article-title":"Metabolomic profiling reveals early biomarkers of gestational diabetes mellitus and associated hepatic steatosis","volume":"24","author":"Jung","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1111\/dom.16233","article-title":"Identification of growth differentiation factor 15 as an early predictive biomarker for metabolic dysfunction-asso steatohepatitis: A nested case-control study of UK Biobank proteomic data","volume":"27","author":"Wang","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"105184","DOI":"10.1016\/j.ebiom.2024.105184","article-title":"Soluble CD46 as a diagnostic marker of hepatic steatosis","volume":"104","author":"Bitterer","year":"2024","journal-title":"EBioMedicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/apt.17564","article-title":"Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD","volume":"58","author":"Kim","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Poynard, T., Deckmyn, O., Pais, R., Aron-Wisnewsky, J., Peta, V., Bedossa, P., Charlotte, F., Ponnaiah, M., Siksik, J.-M., and Genser, L. (2025). Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Diagnostics, 15.","DOI":"10.20944\/preprints202503.2037.v1"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"McHugh, L.C., Snyder, K., and Yager, T.D. (2019). The effect of uncertainty in patient classification on diagnostic performance estimations. PLoS ONE, 14, Erratum in PLoS ONE 2019, 14, e0218492.","DOI":"10.1371\/journal.pone.0218492"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/apt.18478","article-title":"Lubiprostone Reduces Fat Content on MRI-PDFF in Patients with MASLD: A 48-Week Randomised Controlled Trial","volume":"61","author":"Mostafa","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1053\/j.gastro.2025.02.034","article-title":"From \u201cBurnt-Out\u201d to \u201cBurning-Out\u201d: Capturing Liver Fat Loss in Patients with Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease From a Dynamic Perspective","volume":"169","author":"Liu","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e1856","DOI":"10.1210\/clinem\/dgae639","article-title":"Associations Between Visceral and Liver Fat and Cardiac Structure and Function: A UK Biobank Study","volume":"110","author":"Lv","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1038\/s41467-020-15948-9","article-title":"The UK Biobank imaging enhancement of 100,000 participants:\u2009rationale, data collection, management and future directions","volume":"11","author":"Littlejohns","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2337\/dc22-2048","article-title":"High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold","volume":"46","author":"Castera","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Poynard, T., Lebray, P., Ingiliz, P., Varaut, A., Varsat, B., Ngo, Y., Norha, P., Munteanu, M., Drane, F., and Messous, D. (2010). Prevalence of liver fibrosis and risk factors in a general population using noninvasive biomarkers (FibroTest). BMC Gastroenterol., 10.","DOI":"10.1186\/1471-230X-10-40"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e010017","DOI":"10.1136\/bmjopen-2015-010017","article-title":"Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity","volume":"5","author":"Poynard","year":"2015","journal-title":"BMJ Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/MEG.0000000000001064","article-title":"Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference","volume":"30","author":"Poynard","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/jhep.2003.50267","article-title":"Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C","volume":"38","author":"Poynard","year":"2003","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jhep.2017.09.024","article-title":"Back to Byzance: Querelles byzantines over NASH and fibrosis","volume":"67","author":"Ratziu","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","article-title":"Noninvasive Assessment of Liver Fibrosis in NAFLD","volume":"21","author":"Sanyal","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12933-024-02343-7","article-title":"Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease","volume":"23","author":"Chen","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"393","author":"Targher","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1111\/apt.17866","article-title":"Diagnosis and noninvasive assessment of MASLD in type 2 diabetes and obesity","volume":"59","author":"Chan","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12933-024-02161-x","article-title":"Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: A cross-sectional study with two independent cohorts","volume":"23","author":"Denimal","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12933-025-02705-9","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: A prospective cohort study","volume":"24","author":"Denimal","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100928","DOI":"10.1016\/j.jhepr.2023.100928","article-title":"Marked difference in liver fat measured by histology vs. magnetic resonance-proton density fat fraction: A meta-analysis","volume":"6","author":"Qadri","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2025.05.030","article-title":"Clinical utility of phosphatidyl ethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification","volume":"83","author":"Tavaglione","year":"2025","journal-title":"J. Hepatol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/12\/3045\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:23:01Z","timestamp":1765603381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/12\/3045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["biomedicines13123045"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13123045","relation":{},"ISSN":["2227-9059"],"issn-type":[{"type":"electronic","value":"2227-9059"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}